AR030936A1 - Derivados de (tio)urea inhibitorios de factor viia, un proceso para su preparacion y su uso - Google Patents
Derivados de (tio)urea inhibitorios de factor viia, un proceso para su preparacion y su usoInfo
- Publication number
- AR030936A1 AR030936A1 ARP010102657A ARP010102657A AR030936A1 AR 030936 A1 AR030936 A1 AR 030936A1 AR P010102657 A ARP010102657 A AR P010102657A AR P010102657 A ARP010102657 A AR P010102657A AR 030936 A1 AR030936 A1 AR 030936A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- het
- aryl
- alkoxy
- aminocarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Abstract
Derivados de (tio)urea inhibitorios de factor VIIa, que comprende compuestos de la formula (1) en la cual: m es 0, 1, 2, 3, o 4; n es 0, 1, 2, o 3; A es halogeno; X es azufre u oxígeno; R1 se selecciona entre hidrogeno, hidroxi, alcoxicarbonilo C1-12, aril C6-14-alcoxicarbonilo C1-4 y ariloxicarbonilo C6-14, donde cada uno de los grupos arilo es insustituido o sustituido con uno o más sustituyentes idénticos o diferentes seleccionados entre alquilo C1-12, halogeno y alcoxi C1-12; R2 se selecciona entre hidrogeno, alquilo C1-12, arilo C6-14, arilo C6-14-alquilo C1-4, R20-alquilo C1-12, R20-arilo C6-14 y R20-arilo C6-14-alquilo C1-4, donde R20 se selecciona entre hidroxicarbonilo, aminocarbonilo, alcoxicarbonilo C1-12 y arilo C6-14-alcoxicarbonilo C1-4; R3 se selecciona entre hidrogeno, ciano, hidroxi y alquilo C1-12; R4 se selecciona entre alquilo C1-12, arilo C6-14, arilo C6-14-alquilo C1-4, Het y Het-alquilo C1-4, donde los grupos alquilo, arilo y Het son insustituidos o sustituidos con uno o más sustituyentes idénticos o diferentes R10; R5 se selecciona entre hidrogeno, alquilo C1-12, arilo C6-14, arilo C6-14-alquilo C1-4, Het, Het-alquilo C1-4, arilo C6-14-alquilo C1-4-aminocarbonilo y Het-alquilo C1-4-aminocarbonilo, donde los grupos alquilo, arilo y Het son insustituidos o sustituidos con uno o más sustituyentes idénticos o diferentes R10; o R4 y R5 junto con el átomo de C al cual están enlazados forman un anillo de 3-8 miembros, saturado o insaturado, que es un anillo carbocíclico o un anillo heterocíclico que contiene 1, 2 o 3 heteroátomos de anillo idénticos o diferente, seleccionados entre nitrogeno, oxígeno y azufre, y que puede ser condensado a uno o dos sistemas de anillo heterocíclico o sistemas de anillo carbocíclico saturado o insaturado que contienen 5 a 10 átomos de anillo, de los cuales 1, 2 o 3 pueden ser heteroátomos de anillo idénticos o diferentes seleccionados entre nitrogeno, oxígeno y azufre, donde el grupo R4(R5)C resultante es insustituido o sustituido con uno o más sustituyentes idénticos o diferentes R10; R6 se selecciona entre hidrogeno, hidroxi, alcoxi C1-8 y arilo C6-14-alcoxi C1-4; R10 se selecciona entre alquilo C1-12, arilo C6-14-alquilo C1-4, alcoxi C1-8, alcoxi C1-4-alcoxi C2-4, arilo C6-14-alcoxi C1-4, ariloxi C6-14, Het-oxi, Het-alcoxi C1-4, arilo C6-14, Het, Het-alquilo C1-4, trifluorometoxi, trifluorometilo, halogeno, oxo, hidroxi, amino, alquilcarbonilamino C1-12, aminocarbonilamino, arilcarbonilamino C6-14, Het-carbonilamino, arilo C6-14-alquilcarbonilamino C1-4, Het-alquilcarbonilamino C1-4, alquilcarbonilo C1-8, arilcarbonilo C6-14, alquilaminocarbonilo C1-8, arilaminocarbonilo C6-14, arilo C6-14-alquilaminocarbonilo C1-4, Het-aminocarbonilo, Het-alquilaminocarbonilo C1-4, aminocarbonilo, alcoxicarbonilo C1-8, hidroxicarbonilo, ciano, nitro, amidino, acetimino, tri-(alquilo C1-4)amonio, alquilamino C1-8, di-(alquilo C1-8)amino, hidroxicarbonilmetoxi, alquilsulfonilo C1-8, arilsulfonilo C6-14, alquilaminosulfonilo C1-8, arilaminosulfonilo C6-14, arilo C6-14-alquilaminosulfonilo C1-4, Het-aminosulfonilo, Het-alquilaminosulfonilo C1-4, alquilsulfonilamino C1-8, arilsulfonilamino C6-14, arilo C6-14-alquilsulfonilamino C1-4, Het-sulfonilamino y Het-alquilsulfonilamino C1-4, donde alquilcarbonilamino representando R10 es insustituido o sustituido en el grupo alquilo con un sustituyente seleccionado entre amino, hidroxi y alcoxi C1-4, y donde alquilo C1-12 y alcoxi C1-8 representando R10 son insustituidos o sustituidos con uno o más sustituyentes idénticos o diferentes seleccionados entre alcoxicarbonilo C1-8, hidroxicarbonilo y aminocarbonilo, donde cada uno de los grupos arilo y grupo Het en un grupo R10 es insustituido o sustituido con uno o más sustituyentes idénticos o diferentes seleccionados entre halogeno, nitro, oxo, hidroxi, alquilo C1-8, alcoxi C1-8, alcoxi C1-4-alcoxi C2-4, ariloxi C6-14, arilo C6-14-alcoxi C1-4, Het-oxi, Het-alcoxi C1-4, arilo C6-14, arilo C6-14-alquilo C1-4, Het, Het-alquilo C1-4, trifluorometilo, ciano, trifluorometoxi, alquilsulfonilo C1-8, alcoxicarbonilo C1-8, hidroxicarbonilo, aminocarbonilo, amino, alquilamino C1-8, di-(alquilo C1-8)amino, alquilcarbonilamino C1-8, arilo C6-14-alquilcarbonilamino C1-4, arilcarbonilamino C6-14, Het-carbonilamino, Het-alquilcarbonilamino C1-4 y alquilcarbonilo C1-8, donde alquilo C1-8 y alcoxi C1-8 representando un sustituyente en un grupo arilo o grupo Het en un grupo R10, son insustituidos o sustituidos con uno o más sustituyentes idénticos o diferentes seleccionados entre alcoxicarbonilo C1-8, hidroxicarbonilo y aminocarbonilo; con la condicion que, cuando un sustituyente R10 está enlazado a un grupo alquilo, no puede ser alcoxicarbonilo C1-8, hidroxicarbonilo, aminocarbonilo, alquilaminocarbonilo C1-8, o alquilaminosulfonilo C1-8, y que, cuando un sustituyente R10 está enlazado a un grupo alquilo, no puede ser alquilo C1-8 que es sustituido con uno o más sustituyentes idénticos o diferentes seleccionados entre alcoxicarbonilo C1-8, hidroxicarbonilo y aminocarbonilo; Het es un residuo de un sistema de anillo heterocíclico de 3-10 miembros, monocíclico o bicíclico, saturado o insaturado, que contiene 1, 2 o 3 heteroátomos de anillo idénticos o diferentes seleccionados entre nitrogeno, oxígeno y azufre; en todas sus formas estereoisoméricas y mezclas de las mismas en cualquier relacion, y sus sales fisiologicamente tolerables. Los compuestos de la formula (1) son compuestos farmacologicamente activos de valor. Exhiben un fuerte efecto antitrombotico y son adecuados, por ejemplo, para la terapia y profilaxis de enfermedades tromboembolicas y restenosis. Son inhibidores reversibles de la enzima coagulante sanguínea factor VIIa, y en general pueden aplicarse en condiciones en las cuales está presente una actividad indeseada de factor VIIa, o para la curacion o prevencion de las cuales se propone una inhibicion de factor VIIa. Además se relaciona con procesos para la preparacion de compuestos de formula (1), con su uso, en particular como ingredientes activos en productos farmacéuticos, y con preparaciones farmacéuticas que comprenden los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00112116A EP1162194A1 (en) | 2000-06-06 | 2000-06-06 | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR030936A1 true AR030936A1 (es) | 2003-09-03 |
Family
ID=8168926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102657A AR030936A1 (es) | 2000-06-06 | 2001-06-04 | Derivados de (tio)urea inhibitorios de factor viia, un proceso para su preparacion y su uso |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6743790B2 (es) |
| EP (2) | EP1162194A1 (es) |
| JP (1) | JP4809570B2 (es) |
| KR (1) | KR101011345B1 (es) |
| CN (1) | CN1208314C (es) |
| AR (1) | AR030936A1 (es) |
| AU (2) | AU7749401A (es) |
| BR (1) | BR0111264A (es) |
| CA (1) | CA2410862C (es) |
| CZ (1) | CZ20023963A3 (es) |
| DE (1) | DE60139320D1 (es) |
| DK (1) | DK1299354T3 (es) |
| EE (1) | EE200200617A (es) |
| ES (1) | ES2330412T3 (es) |
| HK (1) | HK1055941A1 (es) |
| HR (1) | HRP20020961A2 (es) |
| HU (1) | HUP0301631A2 (es) |
| IL (2) | IL153220A0 (es) |
| MX (1) | MXPA02009789A (es) |
| MY (1) | MY129363A (es) |
| NO (1) | NO328546B1 (es) |
| NZ (1) | NZ522960A (es) |
| PL (1) | PL359584A1 (es) |
| PT (1) | PT1299354E (es) |
| RU (1) | RU2286337C2 (es) |
| SK (1) | SK17032002A3 (es) |
| TW (1) | TWI283662B (es) |
| WO (1) | WO2001094301A2 (es) |
| YU (1) | YU89202A (es) |
| ZA (1) | ZA200209018B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003226755A1 (en) * | 2002-04-27 | 2003-11-17 | Merck Patent Gmbh | Carboxylic acid amides |
| JP2005535710A (ja) * | 2002-08-09 | 2005-11-24 | トランス テック ファーマ，インコーポレイテッド | アリールおよびヘテロアリール化合物ならびに凝固を調節する方法 |
| US7273886B2 (en) * | 2003-05-20 | 2007-09-25 | Genentech, Inc. | Benzofuran inhibitors of factor VIIa |
| JP2007505160A (ja) * | 2003-05-20 | 2007-03-08 | ジェネンテック・インコーポレーテッド | 第ＶＩＩａ因子のアシルスルファミド阻害剤 |
| US7208601B2 (en) * | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7501538B2 (en) * | 2003-08-08 | 2009-03-10 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions and methods of use |
| EP1660439A2 (en) * | 2003-08-08 | 2006-05-31 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| EP1810965A4 (en) * | 2004-10-13 | 2009-10-28 | Eisai R&D Man Co Ltd | HYDRAZIDE DERIVATIVES |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2006089953A1 (en) * | 2005-02-24 | 2006-08-31 | Novo Nordisk Health Care Ag | Compounds for stabilizing factor vii polypeptide formulations |
| JP2008531525A (ja) * | 2005-02-24 | 2008-08-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチド製剤を安定化する化合物 |
| WO2006089952A1 (en) * | 2005-02-24 | 2006-08-31 | Novo Nordisk Health Care Ag | Amidino-compounds por stabilizing factor vii polypeptide formulations |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| CA2647423C (en) | 2006-03-24 | 2015-02-17 | Eisai R&D Management Co., Ltd. | Triazolone derivative |
| US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| WO2007118853A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| JPWO2009038157A1 (ja) * | 2007-09-21 | 2011-01-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ２，３−ジヒドロ−イミノイソインドール誘導体 |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| IN2014DN03424A (es) | 2011-10-26 | 2015-06-05 | Allergan Inc | |
| AU2013249474A1 (en) * | 2012-04-16 | 2014-11-06 | Allergan, Inc. | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| US20150273027A1 (en) * | 2012-10-10 | 2015-10-01 | Novo Nordisk Healthcare Ag | Liquid pharmaceutical composition of factor vii polypeptide |
| CA3133264A1 (en) | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| AU2014226001B2 (en) | 2013-03-06 | 2018-12-06 | Allergan, Inc. | Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273982A (en) * | 1990-03-09 | 1993-12-28 | Hoffmann-La Roche Inc. | Acetic acid derivatives |
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| WO1992013552A1 (en) * | 1991-02-05 | 1992-08-20 | Smithkline Beecham Corporation | Anti-aggregatory peptides containing an aromatic ester or amide |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| JP3387948B2 (ja) * | 1992-12-04 | 2003-03-17 | 富山化学工業株式会社 | 新規なフェニルアラニン誘導体またはその塩 |
| US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
| DE4309867A1 (de) * | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
| GB9313269D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Allophanic acid derivatives |
| GB9313268D0 (en) * | 1993-06-28 | 1993-08-11 | Zeneca Ltd | Chemical compounds |
| WO1995008550A1 (en) * | 1993-09-24 | 1995-03-30 | Abbott Laboratories | Endothelin antagonists |
| CA2174516A1 (en) * | 1993-10-19 | 1995-04-27 | Yoshiharu Ikeda | 2,3-diaminopropionic acid derivative |
| US5674894A (en) * | 1995-05-15 | 1997-10-07 | G.D. Searle & Co. | Amidine derivatives useful as platelet aggregation inhibitors and vasodilators |
| EP0880320A4 (en) * | 1996-01-30 | 1999-06-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| JP3786578B2 (ja) * | 1997-11-18 | 2006-06-14 | 帝人ファーマ株式会社 | 環状アミン誘導体、およびその薬剤としての使用法 |
| EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
-
2000
- 2000-06-06 EP EP00112116A patent/EP1162194A1/en not_active Withdrawn
-
2001
- 2001-05-26 EE EEP200200617A patent/EE200200617A/xx unknown
- 2001-05-26 PT PT01955291T patent/PT1299354E/pt unknown
- 2001-05-26 BR BR0111264-3A patent/BR0111264A/pt not_active IP Right Cessation
- 2001-05-26 IL IL15322001A patent/IL153220A0/xx unknown
- 2001-05-26 KR KR1020027016691A patent/KR101011345B1/ko not_active IP Right Cessation
- 2001-05-26 WO PCT/EP2001/006029 patent/WO2001094301A2/en active IP Right Grant
- 2001-05-26 RU RU2002135308/04A patent/RU2286337C2/ru not_active IP Right Cessation
- 2001-05-26 SK SK1703-2002A patent/SK17032002A3/sk not_active Application Discontinuation
- 2001-05-26 CA CA002410862A patent/CA2410862C/en not_active Expired - Fee Related
- 2001-05-26 PL PL01359584A patent/PL359584A1/xx not_active Application Discontinuation
- 2001-05-26 AU AU7749401A patent/AU7749401A/xx active Pending
- 2001-05-26 EP EP01955291A patent/EP1299354B1/en not_active Expired - Lifetime
- 2001-05-26 HU HU0301631A patent/HUP0301631A2/hu unknown
- 2001-05-26 MX MXPA02009789A patent/MXPA02009789A/es active IP Right Grant
- 2001-05-26 NZ NZ522960A patent/NZ522960A/en unknown
- 2001-05-26 CN CNB018088309A patent/CN1208314C/zh not_active Expired - Fee Related
- 2001-05-26 AU AU2001277494A patent/AU2001277494B2/en not_active Ceased
- 2001-05-26 CZ CZ20023963A patent/CZ20023963A3/cs unknown
- 2001-05-26 DE DE60139320T patent/DE60139320D1/de not_active Expired - Lifetime
- 2001-05-26 JP JP2002501818A patent/JP4809570B2/ja not_active Expired - Fee Related
- 2001-05-26 YU YU89202A patent/YU89202A/sh unknown
- 2001-05-26 DK DK01955291T patent/DK1299354T3/da active
- 2001-05-26 ES ES01955291T patent/ES2330412T3/es not_active Expired - Lifetime
- 2001-06-04 TW TW090113412A patent/TWI283662B/zh not_active IP Right Cessation
- 2001-06-04 AR ARP010102657A patent/AR030936A1/es active IP Right Grant
- 2001-06-05 MY MYPI20012631A patent/MY129363A/en unknown
- 2001-06-06 US US09/874,318 patent/US6743790B2/en not_active Expired - Lifetime
-
2002
- 2002-11-06 ZA ZA200209018A patent/ZA200209018B/en unknown
- 2002-12-02 IL IL153220A patent/IL153220A/en not_active IP Right Cessation
- 2002-12-03 NO NO20025810A patent/NO328546B1/no not_active IP Right Cessation
- 2002-12-05 HR HRP20020961 patent/HRP20020961A2/hr not_active Application Discontinuation
-
2003
- 2003-11-12 HK HK03108194A patent/HK1055941A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR030936A1 (es) | Derivados de (tio)urea inhibitorios de factor viia, un proceso para su preparacion y su uso | |
| AR029215A1 (es) | Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti | |
| AR030553A1 (es) | Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados | |
| AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
| NO308603B1 (no) | Pyrimidinylderivater som interleukininhibitorer, farmasøytisk preparat inneholdende slike derivater samt deres anvendelse | |
| HUP0003929A2 (hu) | Piperazinszármazékok és alkalmazásuk gyulladásgátló hatású gyógyszerkészítmények előállítására, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
| AR032361A1 (es) | Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR048427A1 (es) | Derivados de sulfonilpirroles con actividad inhibitoria de la histona deacetilasa, composiciones farmaceuticas que los contienen y el uso de las mismas para el tratamiento de enfermedades relacionadas. | |
| AR016868A1 (es) | Derivados de 3-amidinoanilina, composicion farmaceutica, un inhibidor del factor x de coagulacion de la sangre activado, usos y procedimiento en lafabricacion de una composicion farmaceutica y de un inhibidor de la prevencion y tratamiento de enfermedades tromboembolicas e intermediarios en la prepa | |
| HUP0401832A2 (hu) | Monociklusos vagy biciklusos karbociklikus és heterociklikus vegyületek mint Xa faktor inhibitorok és ezeket tartalmazó gyógyszerkészítmények | |
| NO20000077D0 (no) | Anvendelse av colchinolderivater som middel for skading av vaskulater | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| PE20050089A1 (es) | Derivados de azo [1,2-c] quinazolina condensados | |
| AR053232A1 (es) | Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico. | |
| ES2158778B1 (es) | Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen. | |
| BR0108613A (pt) | Novo uso de derivados de fenilheteroalquiilamina | |
| ATE380030T1 (de) | Antivirale bicyclo-4.4.0-derivate | |
| FI942423A0 (fi) | Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina | |
| AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
| AR013079A1 (es) | Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios | |
| NO953876D0 (no) | HIV-proteaseinhibitorer som er anvendbare for behandling av AIDS | |
| RU2002135308A (ru) | Производные (тио) мочевины, ингибирующие фактор viiа, их получение и применение | |
| NO331002B1 (no) | Tioxantinderivater og farmasoytiske preparater med tioxantinderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |